Chronic myeloid leukaemia

Surveillance, Epidemiology, and End Results (SEER) Program data (2000-2020) report the following relative survival rates (all stages) by time since diagnosis:[98]National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER explorer [internet publication]. https://seer.cancer.gov/statistics-network/explorer

• 77.9% (2-year survival)

• 66.8% (5-year survival)

• 58% (10-year survival)

Prognosis is poorer for older patients with chronic myeloid leukaemia (CML); 5-year relative survival rates (all stages; 2000-2020) by time since diagnosis:[98]National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER explorer [internet publication]. https://seer.cancer.gov/statistics-network/explorer

• <50 years: 87.5%

• 50-64 years: 78.2%

• ≥65 years: 44.7%

Patients diagnosed and treated in the chronic phase have a significantly better prognosis than those with accelerated- or blast-phase CML. Prognosis for patients with blast crisis remains poor. For more information, see Blast crisis.